Medicus Pharma submits Teverelix Phase 2b/3 registrational protocol to FDA
Medicus said it submitted an optimized seamless Phase 2b/3 registration-intent protocol to the FDA for Teverelix in advanced prostate cancer. The design starts with about 80 randomized patients and expands to about 608 if continuation criteria are met, targeting a registrational pathway in patients at increased cardiov